MINYANVILLE ORIGINAL Elan’s
(ELN) shares took a beating Tuesday morning after the Irish drug company’s partners abandoned a development program
for what was once believed to be a potentially promising treatment for Alzheimer’s disease.
Elan partnered with Johnson & Johnson
(JNJ), which was working with Pfizer
(PFE) to develop bapineuzumab, a drug aimed at treating mild to moderate Alzheimer’s. After an earlier clinical disappointment, the drug failed again in a pivotal study conducted in hopes of eventually winning US approval for the treatment. The companies are giving up on the trial.
Even though the news was mostly expected, investors were fleeing all three companies Tuesday. Elan’s US-traded shares dropped 6% to $10.55 in late-morning trading, Pfizer fell 2% to $23.83, and J&J dipped 1% to $68.44. Shares of Eli Lilly
(LLY), which separately is developing its own Alzheimer’s treatment, slipped more than 2% to $42.67.
Elan gets almost all of its revenue from Tysabri, a multiple sclerosis drug it markets with Biogen Idec
(BIIB). The Alzheimer’s drug represented a new source of sales in an important treatment area. So, what now for Elan?
In a statement, Elan CEO Kelly Martin says his company will focus on Tysabri sales, cost cutting, and a stronger balance sheet “to provide a unique growth and value investment thesis to the marketplace while continuously reducing overall financial risk.”
What Elan should be considering is a strategic alternative, such as a sale to Tysabri partner Biogen, RBC Capital Markets analyst Michael Yee says.
Yee says there’s a bull case for an Elan takeover and he recommends buying the stock. (For one thing, Martin has announced that he’s leaving the company and it’s unclear who will run it. The executive previously said he would stay long enough to see results from the bapineuzumab studies.)
Leerink Swann analyst Marko Kozul doesn’t think Biogen is in any rush to buy Elan, however. And if such a potential transaction should occur, Kozul predicts that it wouldn’t happen until sometime next year after Elan’s shares fall even further. The analyst rates the stock a hold.
Biogen had $2.9 billion in cash and liquid securities as of June 30. Elan’s market cap was $6.2 billion Tuesday morning.
By late morning, Elan’s shares recovered from an earlier double-digit dip. The recovery may be a little premature.
A survey of 181 investors by ISI Group analyst Mark Schoenebaum estimated that the value of the Alzheimer’s treatment was worth about $2 of Elan’s stock price (before the drop on Tuesday). The stock, which fell 24% this year, was down by less than $1 late morning.
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.